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Background: 
M y o f as c ia l p ain  sy n d r o m e  ( M P S )  is  a  r e gio n al m u sc u lo sk e le t al p a in  d iso r d e r  th a t is  c au se d  b y  m y o f as c ia l 
trigger points. The objective of this study was to determine the prevalence of MPS among chronic back pain 
patients, as well as to identify risk factors and the outcome of this disorder.
Methods: 
This was a prospective observational study involving 126 patients who attended the Pain Management Unit 
for chronic back pain between 1st January 2009 and 31st December 2009. Data examined included demographic 
features of patients, duration of back pain, muscle(s) involved, primary diagnosis, treatment modality and 
response to treatment.
Results: 
The prevalence of MPS among chronic back pain patients was 63.5% (n = 80). Secondary MPS was more 
common than primary MPS, making up 81.3% of the total MPS. There was an association between female 
gender and risk of developing MPS (χ
2  = 5.38, P = 0.02, O.R. = 2.4). Occupation, body mass index and 
duration of back pain were not significantly associated with MPS occurrence. Repeated measures analysis 
showed significant changes (P ＜ 0.001) in Visual Analogue Score (VAS) and Modified Oswestry Disability Score 
(MODS) with standard management during three consecutive visits at six-month intervals.
Conclusions: 
MPS prevalence among chronic back pain patients was significantly high, with female gender being a 
significant risk factor. With proper diagnosis and expert management, MPS has a favourable outcome. (Korean 
J  Pain  2011;  24:  100-104)
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INTRODUCTION
    My ofascial pain syndrome (MPS) is a trigger point-in-
duced regional musculoskeletal pain disorder affecting one 
or more muscles or groups of muscles. A myofascial trigger 
point is defined as a hyperirritable spot, usually within a 
taut band of skeletal muscle or in the muscle fascia, which 
is painful on compression and can give rise to character-
istic referred pain, motor dysfunction, and autonomic phe-
nomena [1]. 
    MPS is a common cause of pain and dysfunction in 
the musculoskeletal system. It accounts for 20% to 95% 
of patients with musculoskeletal pain presenting at general 
medical  clinics  and  pain  management  centres  [2-6]. 
Despite the prevalence of MPS, awareness among clini-
cians is still inadequate, which results in this condition of-
ten being misdiagnosed or underdiagnosed and thus un-
der-treated [7-9]. 
    The purpose of this study was to review our experi-
ence with MPS in patients with chronic back pain in order 
to provide local data on prevalence, risk factors and out-
come of patients with MPS. 
MATERIALS  AND  METHODS
    After approval by the Ethics Committee of University 
Science Malaysia, a prospective observational study was 
carried out on 126 consecutive patients who attended the 
Pain  Management  Unit  at  Hospital  University  Science 
Malaysia,  Kelantan,  between  1st  January  and  31st 
December 2009 for chronic back pain (i.e. lasting more 
than 6 months). Data examined included patient demo-
graphic f eatures, duration of back pain, muscle(s) in-
volved, primary diagnosis, treatment modality and re-
sponse to treatment. 
    MPS diagnosis was based upon the presence of a trig-
ger point, reproducible pain, taut band, referred pain and 
jump sign. Initially, patients were requested to point to the 
painful spot with one finger in order to locate a trigger 
point. A trigger point was identified when a painful nodule 
on a muscle was felt through either a flat or pincer pal-
pation technique. During palpation or compression of that 
point, reproduction of recognized pain was taken as one 
of the criteria for MPS diagnosis. A force of approximately 
2 kg was applied in order to palpate the trigger point or 
to elicit reproducible pain. A taut band can be felt as a 
rope-like  induration  that  extends  from  a  trigger  point 
nodule to the attachment of the taut muscle fibers at each 
end of the muscle. The taut band can be snapped or rolled 
under the finger in accessible muscles. Referred pain was 
defined as any pain felt away from the area of palpation. 
The presence of referred pain depends on the amount of 
pressure applied and thus also depends on subcutaneous 
thickness; the pressure of compression was adjusted to a 
constant level by applying digital pressure that caused the 
finger to blanch. When the nail turned pale, the amount 
o f  p r e s s u r e  w a s  m e a s u r e d  t o  b e  a p p r o x i m a t e l y  3  t o  4 
kg/cm
2. Jump sign is a general pain response of the pa-
tient who winces, may cry out or may withdraw in response 
to pressure applied on a trigger point. Subjective com-
p l a i n t s  o f  p a i n  w e r e  m e a s u r e d  u s i n g  a  v i s u a l  a n a l o g u e 
scale (VAS) between 0 and 10. Functional disability was as-
sessed with the Modified Oswestry Disability Score (ODI) 
between 0 and 100.
    All patients with MPS were subjected to standard 
therapy consisting of physical therapy, oral medication and 
exercise. Trigger point injection was given when the initial 
pain score was ＞ 7 or when other modes of therapy failed 
to alleviate pain during subsequent visits. In the event of 
more than one muscle involved in MPS, trigger point in-
jection was given to the most painful muscle. Follow-up visits 
that fell within one month of the specified six monthly inter-
vals were chosen to represent those points in follow-up.
1. Data analysis
    Data were analyzed using SPSS software version 12.0. 
Frequency  and  descriptive  statistics  were  calculated  to 
check all relevant characteristics of the data. χ
2 analysis 
was performed to detect the relationship between MPS oc-
currence and potential risk factors. Differences in VAS and 
ODI during three consecutive visits were measured with 
repeated measure ANOVA. 
RESULTS
    A total of 126 patien ts w ere included in this study. The 
mean age of patients was 48.5 ± 15.0 years, and 61.1% of 
the patients were women. Distribution of socio-demographic 
study variables among patients are shown in Table 1. Eighty out 
of 126 patients fulfilled the MPS criteria, thus giving a preva-
lence of 63.5%. Secondary MPS was the most common type 
(81.2%). Characteristics of MPS are summarized in Table 2. 102 Korean J Pain Vol. 24, No. 2, 2011
Table 1. Demographic Characteristics of all Patients and Patients
With MPS
Sample 
population 
(N = 126)
n (%)
Patients with 
MPS
(N = 80)
n (%)
Gender
  Ma l e
  F e ma l e
Age group (years)
  < 3 0
  3 1 - 4 0
  4 1 - 5 0
  5 1 - 6 0
  > 6 0
Occupation
  Professional
  Ho u s e wi f e
  Technical worker
  F a r me r
  Un i f o r m w o r k e r
  Office worker
  Bu s i n e s s ma n
  Unemployed/retired 
Body mass index
  Un d e rwe i g h t  (＜ 18.5)
  Normal (18.5 to 24.9)
  Overweight (25.0 to 29.9)
  Obese (＞ 30.0)
Duration of back pain
  ＜ 1 year
  1  y e a r
  2  y e a r s
  3  y e a r s
  ＞ 3 years 
49 (38.9)
77 (61.1)
18 (14.3)
21 (16.7)
34 (27.0)
24 (19.0)
29 (23.0)
26 (20.6)
32 (25.4)
7 (5.6)
5 (4.0)
22 (17.5)
9 (7.1)
9 (7.1)
16 (12.7)
4 (3.2)
46 (36.5)
43 (34.1)
33 (26.2)
19 (15.1)
29 (23.0)
27 (21.4)
25 (19.8)
26 (20.6)
25 (31.3)
55 (68.7)
13 (16.2)
14 (17.5)
24 (30.0)
11 (13.8)
18 (22.5)
16 (20.0)
24 (30.0)
4 (5.0)
2 (2.5)
16 (20.0)
5 (6.2)
7 (8.8)
6 (7.5)
2 (2.5)
33 (41.3)
25 (31.2)
20 (25.0)
10 (12.5)
19 (23.7)
18 (22.5)
17 (21.3)
16 (20.0)
Table 2. Characteristics of Myofascial Pain Syndrome 
Frequency (n) Percentage (%)
Type of respondent
  Wi t h  MP S
  Without MPS
Type of MPS
  P r i ma ry
  S e c o n d a ry
Number of muscle involved
  1
  2
  3
  ＞ 3
Presentation of MPS
  Trigger point
  Pain recognition 
  Taut band
  J u mp  s i g n
  R e f e r r e d  p a i n
80
46
15
65
46
22
 7
 5
80
80
29
77
34
63.5
36.5
18.8
81.2
57.5
27.5
 8.8
 6.3
100.0
100.0
36.3
96.3
42.5
Table 3. S e c o n d a ry  Ca u s e s  o f  MP S
n = 65 %
Facet joint disorder
Spinal stenosis
Prolapsed intervertebral disc
Sacro-iliac joint disorder
Failed back surgery syndrome
Spondylosis
Structural defect
Trauma 
Fibromyalgia
Malignancy
Discogenic disorder
28
22
20
17
 9
 5
 3
 3
 1
 1
 1
43.1
33.8
30.8
26.2
13.8
 7.7
 4.6
 4.6
 1.5
 1.5
 1.5
Table 4. Muscles of Myofascial Pain Syndrome in Upper Half of 
the Body
Frequency (n = 22) Percentage (%)
Trapezius
Supraspinatus
Rhomboid
Sternocleidomastoid
Subscapularis
Scalene
Levator scapularis
Infraspinatus
Latissimus
Thoracic paravertebral
20
10
10
 4
 4
 2
 1
 1
 1
 1
90.9
45.5
45.5
18.2
18.2
 9.1
 4.5
 4.5
 4.5
 4.5
Causes of secondary MPS are listed in Table 3. 
    Demographic characteristic of patients and causes of 
secondary MPS were analysed with the χ
2 test to find an 
association with MPS occurrence. Only female gender was 
found  to  be  significantly  associated  with  occurrence  of 
MPS: χ
2  = 5.38, P = 0.02, O.R. = 2.4.
    The m uscles in volved in patients with MPS were cate-
gorized according to their location in the upper or lower half 
of the body (shown in Table 4 and 5, respectively). In the 
upper half of the body, the trapezius was the commonest 
muscle involved, while the piriformis was found to be the 
commonest muscle affected in the lower half of the body.
    Treatment for MPS in this study is shown in Table 6. 
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Table 5. Muscl es of Myofasci al  P ai n Syndr ome i n L ower Hal f of
the Body
Frequency (n = 58) Percentage (%)
Piriformis
Lumbar paravertebral
Gluteus medius
Gluteus mininus
Quadratus lumborum
Gluteus maximus
37
22
 7
 6
 4
 2
63.8
37.9
12.1
10.3
 6.9
 3.5
Table 6. Treatment Modalities of MPS
n%
Physical modalities
Oral medications
  P a r a c e t a mo l
  NS AI Ds *
  Op i o i d
  Mu s c l e  r e l a x a n t
  An x i o l y t i c
  Anti-neuropathic
  Anti-absorptive
Trigger point injection
  No injection
  1  ×
  2  ×
  3  ×
  ＞ 3 ×
Exercise
Intervention under fluoroscopy
  E p i d u r a l  s t e r o i d
  E p i d u r o l y s i s
  Sacro-iliac joint injection
  Sacro-iliac join radiofrequency
  Facet joint injection
  Facet joint radiofrequency
  Intra-discal radiofrequency
  Trigger point injection
  Ne rv e  i n j e c t i o n
  Intra-articular injection 
76
 5
70
37
64
20
53
 3
31
26
11
 8
 4
78
36
 5
21
 1
19
 2
 1
23
 2
 1
95.0
 6.3
87.5
46.3
80.0
25.0
66.3
 3.8
38.8
32.5
13.8
10.0
 5.0
97.5
45.0
 6.3
26.3
 1.3
23.8
 2.5
 1.3
28.8
 2.5
 1.3
*NSAIDs: non-steroidal anti-inflammatory drugs.
Table 7. The Changes of VAS and ODI Over Time 
Baseline mean (SD) 6 months mean (SD) 12 months mean (SD) % change and 95% Cl
P value for change 
from baseline*
VAS
†
ODI
‡
7.31 (1.35)
49.02 (17.85)
4.36 (1.41)
26.43 (12.84)
 3.14 (1.64)
12.99 (8.90)
 57.0 (51.8, 61.1)
73.50 (66.7, 75.1)
＜ 0.0001
＜ 0.0001
*P value from repeated measurements analysis ANOVA, 
†VAS: visual analogue score, 
‡ODI: Oswestry disability score.
exercise and a combination of oral medications. NSAIDs 
were  the  most  frequent  oral  medication  prescribed  to 
patients. Treatment for causes of secondary MPS was done 
under fluoroscopy guidance. Reduction in both VAS and 
ODI was found to be significant, as shown in Table 7. 
DISCUSSION
    In our study, MPS prevalence among our patients was 
63.5%, which is consistent with findings reported in many 
studies  and  review  articles  across  different  populations 
[2,4-6]. This suggests that MPS is a major health problem 
among populations. We had no difficulty in making the di-
agnosis of MPS among our patients as the clinical pre-
sentation was classical. 
    F emale gender was f ound to be a significant risk fac-
tor for developing MPS with an odds ratio of 2.4. This is 
consistent with the findings of Fricton et al. [2] and Drewes 
and Jennum [10], both of which found that MPS is more 
prevalent in female than male patients. This was attributed 
to the hormonal changes in women, whereby pain was re-
ported to increase during the second week of the menstru-
al cycle [11]. More extensive research into this matter is 
warranted in order to establish the possible causal rela-
tionship between female gender and MPS.
    Apart from female gender, other variables were found 
to be insignificant risk factors for MPS. These findings lead 
us to believe that MPS can present in any age group, occu-
pation, or weight, as long as precipitating and perpetuating 
factors are present. Although there are numerous refer-
ences describing the pathogenesis and treatment of MPS, 
there are limited  studies  discussing  its  risk factors [12]. 
Comparison with other studies in the area is also limited.
    Upper back pain is a common symptom of trapezius 
and para spinal muscle MPS. Myofascial trigger point de-
velopment in this area is commonly due to habitual poor 
posture, emotional stress and overuse or secondary to de-
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reported that MPS of the trapezius and scalene muscles 
can  potentially  present  as  a  co-morbidity  of  cervical 
spondylosis. The finding of piriformis being the most com-
mon muscle involved in the lower half of the body is con-
sistent with the statement by Hains [15], 2002 that MPS 
of the piriformis and the muscles around the posterior su-
perior iliac spine, the iliac crest and posterior sacroiliac line 
are common sources of lower back pain. In addition, MPS 
of the piriformis muscle has been recognized as a common 
cause of Piriformis Syndrome, a clinical symptom of scia-
tica secondary to compression or irritation of the sciatic 
nerve by an abnormal piriformis muscle. It has been docu-
mented as a primary or contributory cause for sciatica and 
lower back pain [16].
    The primary goal of management for MPS is to break 
the  vicious  cycle  of  pain  through  elimination  of  trigger 
points. A multi-disciplinary approach is required in man-
aging MPS [17]. In this study, once diagnosed with MPS, 
patients were subjected to proven efficacious treatment, 
which included physical therapy (heat and ultrasound), oral 
medication,  and  exercise  (stretching  and  strengthening) 
with or without trigger point injection [18,19]. Thirty-one 
patients were  not  given  trigger  point  injection  as  14 of 
them claimed to have tolerable pain (VAS ≤ 6), while the 
remaining 17 refused despite having a VAS ≥ 7. For those 
who accepted trigger point injection (n = 49), the majority 
required only one or two injections. Only 4 patients re-
quired more than 3 injections. These patien ts were re-
g a r d e d  a s  h a v i n g  r e f r a c t o r y  M P S ,  a n d  w e r e  o f f e r e d  
Botulinum A injection. Most previously published studies 
measured the efficacy of various treatment modalities for 
MPS based on a short-term outcome. In our study, how-
ever,  we  examined  the  overall  outcome  over  a  twelve- 
month period, which was favourable in terms of reduction 
in V AS and ODI. These findings emphasised that a mul-
ti-disciplinary approach to MPS treatment is required in 
order to provide long-term benefit in pain relief. 
    In conclusion, MPS is common and poses a major 
health problem in the Malaysian population. Furthermore, 
female gender is a significant risk factor for MPS. The out-
come of this syndrome is favourable if proper diagnosis 
and prompt management is undertaken.
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